Search:

Categories list

Generic Ezetimibe - Vytorin, Zetia

News & Dashboard

Search by letter:A B C D E F G H IJK L M N O PQR S T U V W X Y Z

	Generic Vytorin Simvastatin Ezetimibe 10mg + 10/20mg + 10mg
Generic Vytorin is used for treating high cholesterol along with a cholesterol-lowering diet. It works by reducing the amount of cholesterol that your body absorbs from your meals. Lowering cholesterol levels in the blood reduces the chance of heart disease, heart attacks and strokes.
$1.97	Buy now!

	Generic Zetia Ezetimibe 10mg
Generic Zetia is used for treating high blood cholesterol along with a low-fat, low-cholesterol diet. It may be used alone or with other medicines. It is also used to treat high blood sitosterol and campesterol along with diet therapy.
$1.17	Buy now!

Social bookmarks:

Choose your language:

Livesupport x20FREE FREEShipping

Ezetimibe/Simvastatin Combo - MD News (press release)
MD News (press release)Ezetimibe/Simvastatin ComboMD News (press release)For patients with type 2 diabetes who are not meeting recommended low-density lipoprotein cholesterol goals, adding ezetimibe to simvastatin treatment .
KineMed's Study of Merck's Ezetimibe (ZETIA(R)) Invited to Join Best of AHA ... - MarketWatch (press release)
KineMed's Study of Merck's Ezetimibe (ZETIA(R)) Invited to Join Best of AHA .
Impax challenges Vytorin patent - Cardiovascular Business
Impax challenges Vytorin patentCardiovascular BusinessVytorin, a combination of ezetimibe (Zetia, Merck) and simvastatin (Zocor, Merck), is indicated as an adjunct therapy to diet that reduces total cholesterol .
Side effects of Vytorin - Helium
Side effects of VytorinHeliumVyotorin is a combination of Ezetimibe and Simvastatin.
Impax Laboratories initiates Vytorin patent challenge - Pharmaceutical Business Review
Impax Laboratories initiates Vytorin patent challengePharmaceutical Business ReviewImpax Laboratories has initiated a challenge of patents listed by MSP Singapore in connection with Vytorin (ezetimibe/simvastatin), 10mg/80mg.

	Bookmark this site

	Subscribe to the News